Gillian McGovern, Associate Editor

This screening method can help empower patients to better manage their health and seek additional care.

About 62.9% of patients with metabolic dysfunction–associated steatohepatitis (MASH) receiving semaglutide experienced resolution of steatohepatitis without worsening of fibrosis.

Jennifer Guthrie, RPh, district leader at CVS pharmacy describes the different medications to treat allergy symptoms and highlight how CVS stands out when addressing patients’ needs.

Currently, the treatment is undergoing evaluation in a 3-part clinical trial to determine its safety, efficacy, and pharmacokinetics in patients with recurrent advanced/metastatic cancers.

In chronic hepatitis B (CHB) mouse models, the ferritin nanoparticle-preS1 (ferritin-NP-preS1) with small interfering RNA (siRNA) showed 100% and sustained serum HBsAg over an approximate 11-month period.

Reductions of approximately 32% were observed during the study.

Paula E. Voinescu, PhD, MD, emphasized the need for additional research in this area, noting it is both “surprising and upsetting.”

The condition, which is common in patients with chronic kidney disease (CKD), is characterized by skin lesions and currently has no curative treatment.

In the treatment of metabolic dysfunction-associated steatohepatitis (MASH), engineered extracellular vesicles helped mitigate disease progression and did not compromise bone density.

In clinical trials, the dihydroergotamine (DHE) nasal powder had favorable safety profiles and rapid pain relief in patients with migraine with or without aura.

At Baptist Health South Florida, pharmacists are embedded in all areas of cardiovascular care, an expert said.

Nipocalimab the first and only FcRn blocker approved in anti-acetylcholine receptor– or anti-muscle-specific kinase adults and children with generalized myasthenia gravis.

A 15-mg dose with a corticosteroid taper regimen was superior to placebo in sustained remission from week 12 to 52.

Although participants noted symptom relief, there was not a dietary modification uniquely perceived as beneficial.

The treatment received indications as a monotherapy and in combination regimen with carboplatin or cisplatin and gemcitabine.

Because mothers are already at risk of depression postpartum, health care professionals must properly counsel mothers on hormonal contraceptives.

The investigators’ hypothesis is supported by phase 2 trial data in which hydronidone resulted in significant reversal of liver fibrosis in patients with chronic hepatitis B (CHB).

This component of scar tissue may have a role in kidney fibrosis for slowing disease progression and improving outcomes for patients with chronic kidney disease (CKD).

The smartphone application-led delabeling also did not delay surgeries or procedures in the evaluated clinics.

The in vivo gene editing program is designed to eliminate cccDNA and inactive integrated hepatitis B DNA.

The breakthrough designation is supported by clinical data from ongoing phase 1/2 trials.

Children who received antibiotics between birth and 2 years of age were more likely to develop food allergies, allergic rhinitis, and asthma, but not neurodevelopmental conditions.

Traditional risk factors were more contributable to cryptogenic ischemic stroke (CIS) without patent foramen ovale (PFO), whereas nontraditional ones were more critical for CIS with PFO.

Authors of a review published in The Journal of Allergy and Clinical Immunology emphasized that blood eosinophil count and fractional exhaled nitric oxide cannot be relied on.

At 28 to 179 days, COVID-19 infection in patients with preexisting chronic kidney disease (CKD) was associated with an increased risk of composite kidney events.

In mouse models, researchers identified that immune cells within the intestine may prevent unwarranted attacks against harmless food allergens.

Strategies for rescuing PTPRD function in diseased livers could provide potential therapeutic options, according to the study authors.

Promoting weight management prior to pregnancy and in early life may yield stronger cardiovascular and maternal health.

Patients with unresectable or metastatic hepatocellular carcinoma (HCC) receiving this regimen had favorable median overall survival (23.7 months) compared with standard of care (20.6 months).

Nipocalimab with standard of care helped patients with generalized myasthenia gravis (gMG) maintain improvements in daily living and quantitative scores compared with placebo.